Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Spencer

Showing results (31-40 of 311) with videos related to

Pageof 32
Sort By:
Molecular Cell|August 20, 2005
The developmental timing regulator AIN-1 interacts with miRISCs and may target the argonaute protein ALG-1 to cytoplasmic P bodies in C. elegansLei Ding, Andrew Spencer, Kiyokazu Morita, et al.
British Journal of Haematology|January 10, 2006
Central nervous system graft-versus-host disease post allogeneic stem cell transplantJake Shortt, Elspeth Hutton, Mark Faragher, et al.
Investigational New Drugs|November 13, 2009
CYT997 causes apoptosis in human multiple myelomaKatherine Monaghan, Tiffany Khong, Gregg Smith, et al.
British Journal of Haematology|May 23, 2013
Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDACSridurga Mithraprabhu, Tiffany Khong, Simon S Jones, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 13, 2017
Defibrotide for the treatment of sinusoidal obstruction syndrome: evaluation of response to therapy and patient outcomesJohn Coutsouvelis, Sharon Avery, Michael Dooley, et al.
Blood|October 18, 2002
TRAIL-induced apoptosis of authentic myeloma cells does not correlate with the procaspase-8/cFLIP ratioAndrew Spencer, Sung-Lin Yeh, Karly Koutrevelis, et al.
Haematologica|September 6, 2015
Comment on "Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma"Simon J Harrison, Hang Quach, Andrew Spencer, et al.
Leukemia|September 21, 2021
Correction: Liquid biopsy: an evolving paradigm for the biological characterisation of plasma cell disordersSridurga Mithraprabhu, Maoshan Chen, Ioanna Savvidou, et al.
Epigenetics|December 9, 2014
Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myelomaSridurga Mithraprabhu, Anna Kalff, Annie Chow, et al.
Leukemia|July 15, 2021
Liquid biopsy: an evolving paradigm for the biological characterisation of plasma cell disordersSridurga Mithraprabhu, Maoshan Chen, Ioanna Savvidou, et al.
Pageof 32

Showing results (31-40 of 311) with videos related to

Sort By:
Pageof 32
Molecular Cell|August 20, 2005
The developmental timing regulator AIN-1 interacts with miRISCs and may target the argonaute protein ALG-1 to cytoplasmic P bodies in C. elegansLei Ding, Andrew Spencer, Kiyokazu Morita, et al.
British Journal of Haematology|January 10, 2006
Central nervous system graft-versus-host disease post allogeneic stem cell transplantJake Shortt, Elspeth Hutton, Mark Faragher, et al.
Investigational New Drugs|November 13, 2009
CYT997 causes apoptosis in human multiple myelomaKatherine Monaghan, Tiffany Khong, Gregg Smith, et al.
British Journal of Haematology|May 23, 2013
Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDACSridurga Mithraprabhu, Tiffany Khong, Simon S Jones, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 13, 2017
Defibrotide for the treatment of sinusoidal obstruction syndrome: evaluation of response to therapy and patient outcomesJohn Coutsouvelis, Sharon Avery, Michael Dooley, et al.
Blood|October 18, 2002
TRAIL-induced apoptosis of authentic myeloma cells does not correlate with the procaspase-8/cFLIP ratioAndrew Spencer, Sung-Lin Yeh, Karly Koutrevelis, et al.
Haematologica|September 6, 2015
Comment on "Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma"Simon J Harrison, Hang Quach, Andrew Spencer, et al.
Leukemia|September 21, 2021
Correction: Liquid biopsy: an evolving paradigm for the biological characterisation of plasma cell disordersSridurga Mithraprabhu, Maoshan Chen, Ioanna Savvidou, et al.
Epigenetics|December 9, 2014
Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myelomaSridurga Mithraprabhu, Anna Kalff, Annie Chow, et al.
Leukemia|July 15, 2021
Liquid biopsy: an evolving paradigm for the biological characterisation of plasma cell disordersSridurga Mithraprabhu, Maoshan Chen, Ioanna Savvidou, et al.
Pageof 32